Drug intelligence / Profile preview

donepezil + methylphenidate

Development stage
Preclinical
Lead developer
Eisai
Modality
Small Molecules
Administration
Oral, Transdermal
01

Overview

Donepezil + methylphenidate is a combination of two pharmaceutical agents, each with distinct mechanisms of action. Donepezil is an acetylcholinesterase inhibitor primarily used to treat symptoms of Alzheimer's disease by increasing acetylcholine levels in the brain, thereby improving cognitive function and memory. Methylphenidate is a central nervous system stimulant that acts as a norepinephrine and dopamine reuptake inhibitor (NDRI), increasing the concentration of these neurotransmitters in the synaptic cleft, which enhances attention and executive function. This combination may be explored for synergistic effects on cognition or attention in neurodegenerative or neuropsychiatric conditions, though it does not have an established brand name or widespread clinical use as a fixed-dose combination.

02

Targets

AcetylcholinesteraseNET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on donepezil + methylphenidate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on donepezil + methylphenidate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call